Delivery Order SPE2DB20D1047-SPE2DB25FF73F
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,957.94 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (120 mL) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed price delivery order was issued on a non-set-aside basis and represents a pediatric ADHD medication supply under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $3,274.31 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60 ml), a pharmaceutical product used in treating attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order...
- The Defense Logistics Agency awarded a $1,108.41 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price contract utilizes no set-aside designation and is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a pediatric ADHD medication procurement supporting military and federal healthcare systems....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. This is a firm fixed-price delivery order with a ceiling value of $3,763.02 and an ultimate completion date of July 28, 2025. The contract was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in a 60 mL quantity, with a ceiling value of $1,968.69. This is a firm fixed-price delivery order with an ultimate completion date of July 23, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,327.20 firm fixed-price contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has an ultimate completion date of November 24, 2023 and was awarded on November 22, 2023. This delivery order is part...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,974.70 firm fixed-price contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is not set-aside and has an ultimate completion date of May 1, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,051.36 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) on July 24, 2025, with ultimate completion scheduled for July 25, 2025. This competitively awarded, firm fixed-price delivery order is not set-aside and represents performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract operates under AmerisourceBergen Drug Corp's existing...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,121.73 firm-fixed-price delivery order is for the supply of Quillivant XR 25 mg/5 ml suspension, a medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). The contract, which has an ultimate completion date of October 30, 2024, is a part of a larger Indefinite Delivery Contract (IDC) between...
- SPE2DB20D1047Indefinite Delivery Contract
- SPE2DB20D1047-SPE2DB25FF73FDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,202.16 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (150 mL), a medication used to treat attention deficit hyperactivity disorder. The award was made on July 21, 2025, with a completion date of July 22, 2025, under a firm fixed-price delivery order contract with no set-aside designation. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This comprehensive global pharmaceutical support vehicle enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities. The arrangement reflects DLA's strategy to maintain critical pharmaceutical supply chain capabilities through competitively awarded prime vendor contracts serving the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 7/21/25 |